# Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

> **NCT06475820** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 150 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Biphenotypic Acute Leukemia
- Malignant Lymphoma
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT06475820
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2024-07-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475820, "Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06475820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*